nach oben

Journal of Neurology

Erschienen in:

01.12.2015 | Review

Treating relapsing–remitting multiple sclerosis: therapy effects on brain atrophy

verfasst von: Angela Vidal-Jordana, Jaume Sastre-Garriga, Alex Rovira, Xavier Montalban

Erschienen in: Journal of Neurology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system with a complex and heterogeneous pathology that may ultimately lead to neurodegeneration and brain atrophy. Brain volume loss in MS is known to occur early in the disease course and to be clinically relevant, as it has been related to disability progression. Nowadays, brain volume loss is relatively easy to measure with different automated, reproducible and accurate software tools. Therefore, most of (if not all) the newest clinical trials have incorporated brain volume outcomes as a measure of treatment effect. With this review, we aimed to update and summarize all existing data regarding brain volume and RRMS treatment in clinical trials as well as in open-label observational studies of drugs with positive results in its primary outcome in at least one phase III trial as of March 2014.

Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis—the plaque and its pathogenesis. N Engl J Med 354:942–955. doi:10.1056/NEJMra052130 CrossRefPubMed

Miller DH, Barkhof F, Frank JA et al (2002) Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain J Neurol 125:1676–1695CrossRef

Bermel RA, Bakshi R (2006) The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 5:158–170CrossRefPubMed

Smith SM, Zhang Y, Jenkinson M et al (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17:479–489CrossRefPubMed

Zivadinov R, Reder AT, Filippi M et al (2008) Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 71:136–144CrossRefPubMed

Filippi M, Rovaris M, Inglese M et al (2004) Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 364:1489–1496CrossRefPubMed

De Stefano N, Comi G, Kappos L et al (2013) Efficacy of subcutaneous interferon -1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 85:647–653. doi:10.1136/jnnp-2013-306289 PubMedCentralCrossRefPubMed

Kappos L, Freedman MS, Polman CH et al (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370:389–397CrossRefPubMed

Kappos L, Freedman MS, Polman CH et al (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8:987–997CrossRefPubMed

10.

Rudick RA, Fisher E, Lee J-C et al (2000) Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon -1a. Mult Scler 6:365–372. doi:10.1177/135245850000600601 PubMed

11.

Hardmeier M, Wagenpfeil S, Freitag P et al (2005) Rate of brain atrophy in relapsing MS decreases during treatment with IFN -1a. Neurology 64:236–240. doi:10.1212/01.WNL.0000149516.30155.B8 CrossRefPubMed

12.

Kappos L, Traboulsee A, Constantinescu C et al (2006) Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 67:944–953. doi:10.1212/01.wnl.0000237994.95410.ce CrossRefPubMed

13.

Comi G, Martinelli V, Rodegher M et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374:1503–1511CrossRefPubMed

14.

Comi G, Martinelli V, Rodegher M et al (2012) Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler J 19:1074–1083. doi:10.1177/1352458512469695 CrossRef

15.

Ge Y, Grossman RI, Udupa JK et al (2000) Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 54:813–817CrossRefPubMed

16.

Rovaris M, Comi G, Rocca MA et al (2001) Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain J Neurol 124:1803–1812CrossRef

17.

Sormani MP, Rovaris M, Valsasina P et al (2004) Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 62:1432–1434. doi:10.1212/01.WNL.0000120663.85143.B3 CrossRefPubMed

18.

Rovaris M, Comi G, Rocca MA et al (2007) Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. Mult Scler 13:502–508. doi:10.1177/1352458506070704 PubMed

19.

Comi G, Cohen JA, Arnold DL et al (2011) Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol 69:75–82. doi:10.1002/ana.22316 CrossRefPubMed

20.

Mikol DD, Barkhof F, Chang P et al (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7:903–914. doi:10.1016/S1474-4422(08)70200-X CrossRefPubMed

21.

O’Connor P, Filippi M, Arnason B et al (2009) 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8:889–897. doi:10.1016/S1474-4422(09)70226-1 CrossRefPubMed

22.

Lublin FD, Cofield SS, Cutter GR et al (2013) Randomized study combining interferon and glatiramer acetate in multiple sclerosis: the CombiRx Study. Ann Neurol 73:327–340. doi:10.1002/ana.23863 PubMedCentralCrossRefPubMed

23.

Miller DH, Soon D, Fernando KT et al (2007) MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68:1390–1401CrossRefPubMed

24.

Radue E-W, Stuart WH, Calabresi PA et al (2010) Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci 292:28–35. doi:10.1016/j.jns.2010.02.012 CrossRefPubMed

25.

Kappos L, Radue E-W, O’Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387–401CrossRefPubMed

26.

Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402–415CrossRefPubMed

27.

Calabresi PA, Radue E-W, Goodin D et al (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 13:545–556. doi:10.1016/S1474-4422(14)70049-3 CrossRefPubMed

28.

Radue E-W (2012) Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis. Arch Neurol 69:1259. doi:10.1001/archneurol.2012.1051 CrossRefPubMed

29.

Cohen JA, Barkhof F, Comi G et al (2013) Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol 260:2023–2032. doi:10.1007/s00415-013-6932-0 PubMedCentralCrossRefPubMed

30.

Khatri B, Barkhof F, Comi G et al (2011) Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 10:520–529CrossRefPubMed

31.

Arnold DL, Gold R, Kappos L et al (2014) Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 DEFINE study. J Neurol. doi:10.1007/s00415-014-7412-x

32.

Miller DH, Fox RJ, Phillips JT et al (2015) Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology 84:1145–1152. doi:10.1212/WNL.0000000000001360 PubMedCentralCrossRefPubMed

33.

O’Connor P, Wolinsky JS, Confavreux C et al (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365:1293–1303CrossRefPubMed

34.

Wolinsky JS, Narayana PA, Nelson F et al (2013) Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler J 19:1310–1319. doi:10.1177/1352458513475723 CrossRef

35.

Comi G, Jeffery D, Kappos L et al (2012) Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 366:1000–1009CrossRefPubMed

36.

On behalf of the BRAVO Study Group, Vollmer TL, Sorensen PS et al (2014) A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol 261:773–783. doi:10.1007/s00415-014-7264-4 CrossRef

37.

CAMMS223 Trial Investigators, Coles AJ, Compston DAS et al (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359:1786–1801. doi:10.1056/NEJMoa0802670 CrossRef

38.

Cohen JA, Coles AJ, Arnold DL et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380:1819–1828CrossRefPubMed

39.

Coles AJ, Twyman CL, Arnold DL et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380:1829–1839CrossRefPubMed

40.

Paolillo A, Pozzilli C, Giugni E et al (2002) A 6-year clinical and MRI follow-up study of patients with relapsing–remitting multiple sclerosis treated with Interferon-beta. Eur J Neurol 9:645–655CrossRefPubMed

41.

Frank JA, Richert N, Bash C et al (2004) Interferon-β-1b slows progression of atrophy in RRMS: three-year follow-up in NAb− and NAb+ patients. Neurology 62:719–725. doi:10.1212/01.WNL.0000113765.75855.19 CrossRefPubMed

42.

Zivadinov R, Locatelli L, Cookfair D et al (2007) Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler 13:490–501. doi:10.1177/1352458506070446 PubMed

43.

Calabrese M, Bernardi V, Atzori M et al (2011) Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Mult Scler J 18:418–424. doi:10.1177/1352458510394702 CrossRef

44.

Khan O, Bao F, Shah M et al (2012) Effect of disease-modifying therapies on brain volume in relapsing–remitting multiple sclerosis: results of a five-year brain MRI study. J Neurol Sci 312:7–12. doi:10.1016/j.jns.2011.08.034 CrossRefPubMed

45.

Rojas JI, Patrucco L, Miguez J et al (2013) Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis. Neurol Res 36:615–618. doi:10.1179/1743132813Y.0000000304 CrossRefPubMed

46.

Magraner M, Coret F, Casanova B (2012) The relationship between inflammatory activity and brain atrophy in natalizumab treated patients. Eur J Radiol 81:3485–3490. doi:10.1016/j.ejrad.2012.01.028 CrossRefPubMed

47.

Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F et al (2013) Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler J 19:1175–1181CrossRef

48.

Sastre-Garriga J, Tur C, Pareto D et al (2014) Brain atrophy in natalizumab-treated patients: a 3-year follow-up. Mult Scler Houndmills Basingstoke Engl. doi:10.1177/1352458514556300

49.

Rinaldi F, Calabrese M, Seppi D et al (2012) Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. Mult Scler J 18:1760–1767. doi:10.1177/1352458512447704 CrossRef

50.

Portaccio E, Stromillo ML, Goretti B et al (2013) Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, non-randomized pilot study. Eur J Neurol 20:986–990. doi:10.1111/j.1468-1331.2012.03882.x CrossRefPubMed

51.

Zivadinov R (2005) Reproducibility and accuracy of quantitative magnetic resonance imaging techniques of whole-brain atrophy measurement in multiple sclerosis. J Neuroimaging 15:27–36. doi:10.1177/1051228404271010 CrossRefPubMed

52.

Huppertz H-J, Kröll-Seger J, Klöppel S et al (2010) Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structures. Neuroimage 49:2216–2224. doi:10.1016/j.neuroimage.2009.10.066 CrossRefPubMed

53.

Dalton CM, Chard DT, Davies GR et al (2004) Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 127:1101–1107. doi:10.1093/brain/awh126 CrossRefPubMed

54.

Perez-Miralles F, Sastre-Garriga J, Tintore M et al (2013) Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler J 19:1878–1886. doi:10.1177/1352458513488231 CrossRef

55.

Racke MK, Lovett-Racke AE, Karandikar NJ (2010) The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 74:S25–S30CrossRefPubMed

56.

Thöne J, Ellrichmann G, Seubert S et al (2012) Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol 180:267–274. doi:10.1016/j.ajpath.2011.09.037 CrossRefPubMed

57.

Freedman MS, Kaplan JM, Markovic-Plese S (2013) Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis. J Clin Cell Immunol 4:152. doi:10.4172/2155-9899.1000152 CrossRef

58.

Colombo E, Di Dario M, Capitolo E et al (2014) Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide. Ann Neurol 76:325–337. doi:10.1002/ana.24217 CrossRefPubMed

59.

Groves A, Kihara Y, Chun J (2013) Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 328:9–18. doi:10.1016/j.jns.2013.02.011 PubMedCentralCrossRefPubMed

60.

Miron VE, Schubart A, Antel JP (2008) Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 274:13–17. doi:10.1016/j.jns.2008.06.031 CrossRefPubMed

61.

Coelho RP, Payne SG, Bittman R et al (2007) The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 323:626–635. doi:10.1124/jpet.107.123927 CrossRefPubMed

62.

Kelland EE, Gilmore W, Hayardeny L et al (2014) In vitro assessment of the direct effect of laquinimod on basic functions of human neural stem cells and oligodendrocyte progenitor cells. J Neurol Sci 346:66–74. doi:10.1016/j.jns.2014.07.058 CrossRefPubMed

63.

Kerschensteiner M, Gallmeier E, Behrens L et al (1999) Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 189:865–870PubMedCentralCrossRefPubMed

64.

Dhib-Jalbut S, Marks S (2010) Interferon-β mechanisms of action in multiple sclerosis. Neurology 74:S17–S24CrossRefPubMed

65.

Ransohoff RM (2007) Natalizumab for multiple sclerosis. N Engl J Med 356:2622–2629CrossRefPubMed

66.

Linker RA, Lee D-H, Ryan S et al (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain J Neurol 134:678–692. doi:10.1093/brain/awq386 CrossRef

67.

Bar-Or A, Pachner A, Menguy-Vacheron F et al (2014) Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 74:659–674. doi:10.1007/s40265-014-0212-x PubMedCentralCrossRefPubMed

68.

De Stefano N, Filippi M, Miller D et al (2007) Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology 69:1942–1952. doi:10.1212/01.wnl.0000291557.62706.d3 CrossRefPubMed

69.

Sormani MP, Arnold DL, De Stefano N (2014) Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 75:43–49. doi:10.1002/ana.24018 CrossRefPubMed

Titel: Treating relapsing–remitting multiple sclerosis: therapy effects on brain atrophy
verfasst von: Angela Vidal-Jordana
Jaume Sastre-Garriga
Alex Rovira
Xavier Montalban
Publikationsdatum: 01.12.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 12/2015
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-015-7798-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Treating relapsing–remitting multiple sclerosis: therapy effects on brain atrophy

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2015

Thrombectomy assisted by carotid stenting in acute ischemic stroke management: benefits and harms

Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis

Variants in KIF1A gene in dominant and sporadic forms of hereditary spastic paraparesis

Morphometric changes in the reward system of Parkinson’s disease patients with impulse control disorders

Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia

Autonomic dysfunction in subjects at high risk for Parkinson’s disease

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie